Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Core Insights - The company has rebranded to Metagenomi Therapeutics, Inc. to reflect its strategic focus on advancing its lead program in hemophilia A and other promising technologies [1][2] - The MGX-001 program has shown curative factor VIII (FVIII) activity in non-human primates, with plans for IND/CTA submissions by the end of 2026 and a first-in-human study anticipated in 2027 [2][4] - The company expects its cash runway to extend through the fourth quarter of 2027, supporting its ongoing development efforts [2][12] Pipeline Advancements - MGX-001 has demonstrated durable FVIII activity over a 19-month study in non-human primates, with no off-target editing detected [6][10] - The company is exploring the potential of the MGX-001 system for treating other secreted protein deficiencies, including Antithrombin (AT-III) deficiency [7][10] - Recent strategic prioritization has strengthened the company's balance sheet and focused its pipeline on high-value therapeutic programs [12] Corporate Updates - The company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer, emphasizing a commitment to delivering curative genetic medicines [12] - Metagenomi Therapeutics aims to leverage its proprietary gene-editing technologies to expand its pipeline and address various genetic disorders [9][10]